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The type 1 cannabinoid receptor (CB1) is a crucial modulator of
synaptic transmission in the brain. Animal and postmortem human
data suggest that mutant huntingtin represses CB1 transcription.
Our aim was to measure CB1 levels in the brains of Huntington
disease (HD) patients in vivo. Methods: Twenty symptomatic HD
patients and 14 healthy controls underwent PET with the novel
CB1 ligand N-[2-(3-cyano-phenyl)-3-(4-(2-18F-fluorethoxy)phenyl)-
1-methylpropyl]-2-(5-methyl-2-pyridyloxy)-2-methylproponamide.
Results: We observed a profound decrease of CB1 availability
throughout the gray matter of the cerebrum, cerebellum, and
brain stem in HD patients, even in early disease stages. Disease
burden ([number of CAG repeats in the HTT gene – 35.5] · age)
was inversely correlated with CB1 availability in the prefrontal
and premotor cortex. Conclusion: The profound early and
widespread reduction of CB1 availability in vivo is consistent
with the hypothesis that mutant huntingtin represses CB1 tran-
scription. This is the first, to our knowledge, in vivo demonstra-
tion of disturbance of the endocannabinoid system in a human
neurologic disease.
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The type 1 cannabinoid receptor (CB1) is a key modu-
lator of synaptic transmission in the mammalian brain. CB1
is abundantly expressed on presynaptic terminals, where its
activation suppresses neurotransmitter release (1). CB1 can
be activated by D9-tetrahydrocannabinol, the active ingre-
dient of marijuana, but also by endogenous agonists (endo-
cannabinoids). CB1 signaling is involved in the physiologic
regulation of motor behavior, cognition, emotion, and food
intake and also in pathologic processes in animal models of
movement disorders (2) and addiction (3). Whether distur-
bances of the endocannabinoid system (ECS) also play a
role in neurologic diseases in humans remains more spec-
ulative.
Huntington disease (HD) is a dominantly inherited
neurodegenerative disease manifested by motor, cognitive,
and psychiatric dysfunction (4). Neuroimaging and patho-
logic studies indicate that neurodegeneration in HD is
regionally selective and preferentially affects the striatum
and cerebral cortex, whereas other brain areas remain
largely spared until advanced disease stages (5,6). HD
is caused by expansion of a number (n) of CAG repeats
in the HTT gene ([CAG]n), leading to an expanded poly-
glutamine tract in huntingtin, a protein with unknown
function and abundant, ubiquitous expression in the brain.
Accumulating evidence suggests that the expanded poly-
glutamine tract leads to aberrant interactions between mu-
tant huntingtin and nuclear transcription factors, thereby
disturbing the transcription of a subset of genes (7). Several
transcriptionally active drugs ameliorate the HD phenotype
in preclinical trials, further supporting a role for transcrip-
tional dysregulation in HD pathogenesis (8). Interestingly,
CB1 messenger RNA (mRNA) is one of the most consis-
tently decreased transcripts in postmortem striatal tissue
from a range of transgenic HD mouse models and HD
patients (9). Furthermore, a loss of CB1 protein was dem-
onstrated in the basal ganglia of deceased HD patients (10).
Whether CB1 levels are changed in HD brains in vivo is
unknown.
In vivo imaging of CB1 in the human brain has recently
become feasible using quantitative PET with the highly
selective, high-affinity CB1 radioligand N-[2-(3-cyano-
phenyl)-3-(4-(2-18F-fluorethoxy)phenyl)-1-methylpropyl]
-2-(5-methyl-2-pyridyloxy)-2-methylproponamide (18F-
MK-9470) (11). The aim of the present study was to inves-
tigate CB1 availability in the brains of HD patients in
vivo.
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MATERIALS AND METHODS
Subjects
We recruited 20 patients with symptomatic HD and 14 age- and
sex-matched healthy controls. The study was approved by the
institutional Ethics Committee and performed in accordance with
the World Medical Association Declaration of Helsinki. Written
informed consent was obtained from all subjects or their legal
representatives before the study.
Patients with past or current alcohol or drug abuse were
excluded. All HD patients were symptomatic, as defined by the
presence of visible chorea, and had a (CAG)n of at least 39. The
Unified Huntington’s Disease Rating Scale (UHDRS) motor and
total functional capacity (TFC) scores (12) were obtained on or
around the day of PET (mean interval, 0.5 d; range,258 to127 d).
The HD study population covered the entire spectrum of sympto-
matic disease severity (Table 1).
In total, 50 healthy controls between 18 and 70 y were recruited
prospectively for different ongoing studies. Age- and sex-matching
was performed in this study because a previous 18F-MK-9470 PET
study in healthy controls showed significant variation of CB1 map-
ping with age and sex (13). To also match body mass index, the 2
volunteers with the highest bodymass index were excluded, and the
other 14 age-matched controls were retained. Inclusion and exclu-
sion criteria for controls were as previously described (13).
All subjects in this study underwent physical examination and
blood and urine testing to exclude major internal pathology. Urine
toxicology for cannabis and all major known addictive drugs was
performed (13); only nonsmokers (for at least 6 mo) were included.
Methods of radiotracer preparation, imaging, image processing,
data analysis, and analysis design are described in the supple-
mental materials (available online only at http://jnm.snmjournals.
org).
RESULTS
Patient Characteristics
Patient demographics and disease characteristics are
summarized in Table 1. Seven HD patients were in Shoulson–
Fahn stage I and thus represented the earliest phase of
symptomatic disease. The number of (CAG) repeats corre-
lated strongly with age at the time of study (r520.81, P5
21025) and age at symptom onset (r520.90, P5 21027).
The TFC score correlated with motor score (r520.86; P5
11026) and disease duration (r 5 20.77, P 5 71025).
MRI
As expected, we detected substantial reductions of caudate
and putamen volumes in HD patients and smaller changes in
the relative volumes of gray matter, white matter, and
cerebrospinal fluid (Table 2). TFC scores inHDpatients were
correlatedwith caudate volume (r5 0.72,P5 0.0002), puta-
men volume (r5 0.58, P5 0.009), and relative gray-matter
volume (r5 0.50, P 5 0.028) and inversely correlated with
relative cerebrospinal fluid volume (r520.79,P5 61025).
UHDRS motor scores in HD patients were correlated with
relative cerebrospinal fluid volume (r 5 0.70, P 5 0.0008)
and inversely correlated with caudate volume (r 5 20.66,
P 5 0.002), putamen volume (r 5 20.50, P 5 0.028), and
relative gray-matter volume (r520.64,P5 0.003). Disease
TABLE 1. Demographic and Clinical Characteristics of Subjects
HD
Parameter All (n 5 20) Early (n 5 7) Control (n 5 14)
Sex (n)
M 8 3 6
F 12 4 8
Age (y) 53.3 6 12.1 (32.3–83.1) 47.3 6 11.6 (32.3–64.5) 54.3 6 12.9 (30.7–68.5)
Weight (kg) 65.9 6 11.1 (50.0–89.0)* 71.7 6 9.9 (60.0–89.0) 75.7 6 10.6 (58.0–95.0)
(CAG)n 43.6 6 2.8 (39–50) 44.3 6 3.9 (40–50) —
Estimated disease duration (y) 6.0 6 5.5 (0.5–19.4) 1.9 6 1.5 (0.5–4.5) —
UHDRS motor score 35.2 6 25.0 (8–80) 15.0 6 6.1 (8–27) —
UHDRS TFC score 6.4 6 4.8 (0–13) 11.9 6 0.9 (11–13) —
Shoulson–Fahn stage —
I 7 7
II 3 0
III 4 0
IV 4 0
V 2 0
Handedness
L 2 0 3
Ambidexter 0 0 1
R 18 7 10
*Significant difference between patients and controls (P , 0.05).
Values represent mean 6 SD, with range in parentheses. UHDRS motor scale ranges from 0 to 124, with higher scores indicating
more motor impairment. UHDRS TFC scale assesses ability to perform daily activities and ranges from 13 (no impairment) to 0 (total
incapacity). TFC scores are further subdivided into 5 Shoulson–Fahn stages: I (representing TFC scores 11–13), II (scores 7–10), III
(scores 3–6), IV (scores 1–2), and V (score 0).
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burden (reflected by ([CAG]n2 35.5) · age), which has been
shown to correlate with neuropathologic striatal damage
(14), was inversely correlated to caudate volume (r 5
20.44, P 5 0.05). There was no significant correlation
between these volumetric measures and (CAG)n.
CB1 PET
Parametric images of partial-volume–corrected 18F-
MK9470 modified standardized uptake value, reflecting
receptor availability (supplemental materials), showed a
widespread decrease of CB1 in HD patients, compared with
controls (Fig. 1). Statistical parametric mapping analysis
showed highly significant reductions of CB1 availability
in the HD group in all gray-matter regions at a cluster of
P value of less than 0.0001 and familywise error–corrected
height threshold of less than 0.05. When age, sex, and
weight were explicitly taken as nuisance variables, group
differences in statistical parametric mapping still showed
similar results. Volume-of-interest–based statistical analysis
showed that regional variation of the CB1 decrease in HD
was overall relatively small between gray-matter regions:
reductions of CB1 availability ranged from approximately
15% in the cerebellum to approximately 25% in the frontal
cortex (Fig. 2; Supplemental Table 1). No significant differ-
ences in white-matter signal were found between the 2
groups. Without partial-volume correction, similar reduc-
tions of CB1 availability were found in the HD group (Sup-
plemental Table 1).
Importantly, the reduction of CB1 availability throughout
the gray matter occurred early in the course of HD, as shown
by analysis of the subgroup of 7 HD patients in the mildest
stage of symptomatic disease (Figs. 1 and 2). Because a sig-
nificant decrease of similar magnitude was found when only
those HD patients (n 5 7) who did not take any medication
(data not shown) were included, the widespread reduction of
CB1 availability was not due to medication use.
We found no correlations between CB1 availability and
UHDRS motor scores, TFC scores, disease duration, or
(CAG)n. However, a modest inverse correlation was
observed between CB1 availability and ([CAG]n 2 35.5) ·
age for a cluster in the frontal cortex (frontal volume of
interest, r 5 20.49, P 5 0.04; Fig. 3). This correlation was
most pronounced in the prefrontal cortex (frontopolar, Brod-
mann area 10, r 5 20.59, P 5 0.010) and premotor cortex
(Brodmann area 6, r 5 20.50, P 5 0.03).
DISCUSSION
This study is the first, to our knowledge, in vivo dem-
onstration of disturbance of the ECS in a human neurologic
disease. The reduction of CB1 availability in the HD brain
was profound and surprisingly widespread, affecting the
entire gray matter of the cerebrum, brain stem, and cerebel-
lum, even in the earliest symptomatic stage of the disease.
The widespread and relatively uniform reduction of CB1
availability throughout the gray matter in early HD contrasts
with the regional selectivity of early disease changes detected
in previous neuropathologic, MRI, and PET studies. Neuro-
nal cell loss and huntingtin aggregates tend to be mostly
confined to the striatum in early HD, whereas other brain
areas show neuropathologic changes only in more advanced
disease stages (5). Similarly, volumetric MRI in early HD
detected atrophy of the striatum and parts of the cerebral
cortex and hypothalamus, whereas volume loss was minimal
TABLE 2. Volumetric Cerebral and Striatal Data in HD Patients Versus Controls
Parameter HD (n 5 19) Control (n 5 14)
Gray-matter volume (relative to intracranial volume) 0.447 6 0.031* 0.474 6 0.018
White-matter volume (relative to intracranial volume) 0.248 6 0.033 0.273 6 0.016
Cerebrospinal fluid volume (relative to intracranial volume) 0.305 6 0.041* 0.253 6 0.019
Mean caudate volume† (cm3) 1.13 6 0.47‡ 3.69 6 0.35
Mean putamen volume† (cm3) 1.54 6 0.68‡ 3.78 6 0.55
*P , 0.01.
†Mean of left and right sides.
‡P , 10210 vs. controls.
FIGURE 1. Cross-sectional, partial-volume corrected,
modified standardized uptake value (mSUV) parametric
images, averaged for all controls (n 5 14), early-HD
patients (n 5 7), and total group of HD patients (n 5 19).
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or undetectable in most other gray-matter regions such as
the cerebellum (6,15). 18F-FDG PET studies in early HD
revealed significant reductions in glucose metabolism in
the striatum and cerebral cortex but not elsewhere (16,17),
and even in advanced stages, changes in glucose metabolism
remained minimal in areas such as the cerebellum and thala-
mus (17,18). It is interesting to compare our CB1 PET results
with PET studies that used tracers for other neuronal mem-
brane receptors. Dopamine D2 receptor binding is reduced in
the striatum and regions of the cerebral cortex in HD (19,20),
but there have been no reports of studies with high-affinityD2
receptor tracers that would allow a full assessment of changes
in extrastriatal D2 receptors. A PET study with the g-amino-
butyric acid A receptor tracer 11C-flumazenil in 6 patients
with early HD found a significant reduction of receptor den-
sity in the caudate but not in the cerebral cortex, thalamus,
cerebellum, or pons (21). Finally, a study with the opioid
receptor tracer 11C-diprenorphine in 5 early-stage HD
patients found tracer binding changes in the striatum, cingu-
late cortex, thalamus, and prefrontal cortex but not elsewhere
(22). Data in these cited PET studies were not corrected for
partial-volume effects and may have been confounded by
regional volume loss.
Thewidespread distribution of the CB1 changes in HD fits
well with the reported repressive effect of mutant huntingtin
on CB1 transcription (9), given the ubiquitous expression
pattern of mutant huntingtin and the transcription factors it
interacts with (7). However, our findings could also be due to
other contributing mechanisms such as increased degrada-
tion of CB1 mRNA or protein, impaired translation or traf-
ficking, or changes in receptor affinity. Irrespective of the
underlying mechanism, our findings strongly suggest that
the ECS is hypoactive in HD. Given the crucial role of CB1
signaling in the regulation of neurotransmitter release, the
reduction of CB1 levels would be expected to disturb synap-
tic transmission. It will be important to investigate the rela-
tionship between the CB1 changes and various cognitive
and psychiatric symptoms of HD, especially because we
found an inverse correlation between disease burden and
CB1 availability in the prefrontal cortex. Intriguingly, a
recent double-blind, placebo-controlled pilot study of nabi-
lone, a CB1 agonist, in HD patients found evidence sugges-
tive of neuropsychiatric improvement in the nabilone arm
(23). Given the likely involvement of excitotoxicity in HD
and the antiexcitotoxic effect of CB1 activation (24), the loss
FIGURE 2. Bar chart of regional
differences in CB1 availability (18F-
MK-9470 binding) between HD and
controls after partial-volume correction.
***P , 0.001 vs. controls. Mes temp 5
mesial temporal; mSUV 5 modified
standardized uptake value; n.s. 5 not
significant. Error bars indicate 1 SD.
FIGURE 3. Surface rendering of voxel-based correlation
between absolute CB1 availability and disease burden
([(CAG)n – 35.5] · age) at peak height threshold Pheight ,
0.005 (uncorrected). Clusters are overlaid on surface-
rendered average image of HD patients.
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of CB1 might also exacerbate neuronal injury in vulnerable
brain regions.
There was a modest inverse correlation between disease
burden and CB1 availability in the prefrontal and premotor
cortex but not in other brain regions such as the striatum. The
rather stable low-level CB1 availability in the striatumduring
symptomatic HD progression is reminiscent of transgenic
HDmouse data showing that striatal CB1 mRNA declines in
the presymptomatic phase but reaches a steady-state low
level around the onset of overt symptoms. However, CB1
availability in the brain tends to increase with age in healthy
humans, especially inwomen (13). Thus, the relative stability
ofCB1 availability inmost brain regions during symptomatic
HD progression represents a deviation from the pattern
observed with healthy aging.
The profoundly decreased CB1 availability in patients
with early symptomatic HD suggests that the decline in CB1
levels already begins in the presymptomatic phase of HD.
Therefore, it will be important to track the evolution of CB1
levels in premanifest carriers of the HD mutation and
determine whether CB1 PET could provide a biomarker for
the earliest subclinical disease changes. It will be important
to investigate whether administration of CB1 agonists,
elevation of endocannabinoid levels, or delay of the loss of
CB1—for instance, by providing a stimulating environment
(25)—might be of benefit in the treatment of HD.
CONCLUSION
Our data show awidespread disturbance of the ECS in HD
brains in vivo. Our findings suggest that some of the
deleterious effects of mutant huntingtin may in fact be as
ubiquitous as the expression of the mutant protein itself.
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